{
  "abstract": "Background: Vaccine-induced neutralising antibodies are a well-established correlate of protection against acquisition of COVID-19. Vaccine protection from severe COVID-19 remains high, although the role of neutralising antibodies and the contribution of other immune responses to protection from severe outcomes is less clear. Improving understanding of how vaccines prevent severe outcomes is important for future vaccine development. Methods and findings: Here we undertake a systematic search of the literature to obtain estimates of vaccine protection against progression from SARS-CoV-2 infection to severe COVID-19 (hospital or ICU admission). We aggregate results from 25 published clinical studies of vaccine protection from progression to severe outcomes in people with SARS-CoV-2 infection. We match this clinical data to data from 301 studies of post-vaccination neutralisation titres induced by various vaccines against different SARS-CoV-2 variants from the publicly available Stanford University Coronavirus antiviral and resistance database. We then synthesise the data using meta-regression. Neutralising antibody titres were found to be associated with vaccine protection against progression to severe COVID-19 (relative risk (RR) 0.57 per 10-fold increase in GMT, 95% CI [0.51,0.64], p < 0.001). We found that the protection against progression provided by vaccination was higher than that provided by therapeutic passive administration of antibodies, when used to treat individuals with confirmed infection. The main methodological limitations were the fact that neutralisation titres and clinical outcomes were measured in different studies, and the possibility of unmeasured confounding. Conclusions: Together, this work suggests that vaccine-induced neutralising antibodies are correlated with protection from progression to severe COVID-19 and can account for at least a partial mechanistic role in this protection. However, a protection gap remains between the high levels of protection against progressing to severe COVID-19 afforded by vaccination, compared to that afforded by therapeutic administration of antibodies, suggesting other immune responses may also play a role. Why was this study done?: What did the researchers do and find?: What do these findings mean?:",
  "abstract_shown": true,
  "affiliations": [
    "Kirby Institute, University of New South Wales, Sydney, Australia",
    "Faculty of Medicine and Health, Sydney School of Public Health, University of Sydney, Sydney, New South Wales, Australia",
    "School of Mathematics and Statistics, University of New South Wales, Sydney, Australia",
    "Department of Microbiology and Immunology, University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia",
    "Melbourne Sexual Health Centre and Department of Infectious Diseases, Alfred Hospital and Central Clinical School, Monash University, Melbourne, Victoria, Australia"
  ],
  "article_type": "Research Article",
  "arxiv": null,
  "author_total": 10,
  "authors": [
    {
      "affs": [
        0
      ],
      "name": "Karen M. Elias"
    },
    {
      "affs": [
        1
      ],
      "name": "Ainslie Mitchell"
    },
    {
      "affs": [
        2
      ],
      "name": "Eva Stadler"
    },
    {
      "affs": [
        3
      ],
      "name": "Timothy E. Schlub"
    },
    {
      "affs": [
        4
      ],
      "name": "Shanchita R. Khan"
    },
    {
      "name": "Claire Xue"
    },
    {
      "name": "Stephen J. Kent"
    },
    {
      "name": "Deborah Cromer"
    },
    {
      "name": "Miles P. Davenport"
    },
    {
      "name": "David S. Khoury"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/c6sydarvyny0d.bib",
  "cited_by": 0,
  "doi": "10.1371/journal.pmed.1005230",
  "fulltext_url": "https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1005230",
  "id": "c6sydarvyny0d",
  "issns": [
    "1549-1676"
  ],
  "landing_url": "https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1005230",
  "language": null,
  "licence": "CC-BY-4.0",
  "licence_label": "CC BY 4.0",
  "licence_source": "journal",
  "licence_url": "https://creativecommons.org/licenses/by/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "openalex",
      "2725|SARS-CoV-2 and COVID-19 Research"
    ],
    [
      "plos",
      "/Biology and life sciences/Biochemistry/Proteins/Immune system proteins/Antibodies"
    ],
    [
      "plos",
      "/Biology and life sciences/Immunology/Clinical immunology/Antibody therapy"
    ],
    [
      "plos",
      "/Biology and life sciences/Immunology/Immune system proteins/Antibodies"
    ],
    [
      "plos",
      "/Biology and life sciences/Immunology/Vaccination and immunization"
    ],
    [
      "plos",
      "/Biology and life sciences/Immunology/Vaccination and immunization/Vaccine development"
    ],
    [
      "plos",
      "/Biology and life sciences/Microbiology/Medical microbiology/Microbial pathogens/Viral pathogens/Coronaviruses/SARS coronavirus/SARS CoV 2"
    ],
    [
      "plos",
      "/Biology and life sciences/Organisms/Viruses/RNA viruses/Coronaviruses/SARS coronavirus/SARS CoV 2"
    ],
    [
      "plos",
      "/Biology and life sciences/Organisms/Viruses/Viral pathogens/Coronaviruses/SARS coronavirus/SARS CoV 2"
    ],
    [
      "plos",
      "/Biology and life sciences/Physiology/Immune physiology/Antibodies"
    ],
    [
      "plos",
      "/Medicine and health sciences/Clinical medicine/Clinical immunology/Antibody therapy"
    ],
    [
      "plos",
      "/Medicine and health sciences/Epidemiology/Medical risk factors"
    ],
    [
      "plos",
      "/Medicine and health sciences/Immunology/Clinical immunology/Antibody therapy"
    ],
    [
      "plos",
      "/Medicine and health sciences/Immunology/Immune system proteins/Antibodies"
    ],
    [
      "plos",
      "/Medicine and health sciences/Immunology/Vaccination and immunization"
    ],
    [
      "plos",
      "/Medicine and health sciences/Immunology/Vaccination and immunization/Vaccine development"
    ],
    [
      "plos",
      "/Medicine and health sciences/Medical conditions/Infectious diseases/Infectious disease control/Vaccines"
    ],
    [
      "plos",
      "/Medicine and health sciences/Medical conditions/Infectious diseases/Viral diseases/COVID 19"
    ],
    [
      "plos",
      "/Medicine and health sciences/Oncology/Cancer treatment/Antibody therapy"
    ],
    [
      "plos",
      "/Medicine and health sciences/Pathology and laboratory medicine/Pathogens/Microbial pathogens/Viral pathogens/Coronaviruses/SARS coronavirus/SARS CoV 2"
    ],
    [
      "plos",
      "/Medicine and health sciences/Public and occupational health/Preventive medicine/Vaccination and immunization"
    ],
    [
      "plos",
      "/Medicine and health sciences/Public and occupational health/Preventive medicine/Vaccination and immunization/Vaccine development"
    ]
  ],
  "openalex": "W7206161436",
  "pdf_url": "https://journals.plos.org/plosmedicine/article/file?id=10.1371/journal.pmed.1005230&type=printable",
  "pmcid": null,
  "pmid": null,
  "published": "2026-09-02",
  "publisher": "Public Library of Science",
  "ris": "https://research.draconitic.com/paper/c6sydarvyny0d.ris",
  "sources": [
    {
      "first_seen": "2026-10-30T12:18:02Z",
      "native_id": "10.1371/journal.pmed.1005230",
      "source": "plos",
      "url": "https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1005230"
    }
  ],
  "subjects": [
    {
      "field": "biology",
      "origin": "plos:immunology",
      "subfield": "immunology"
    }
  ],
  "title": "Neutralising antibodies and protection from progression to severe COVID-19: A meta-analysis",
  "title_text": "Neutralising antibodies and protection from progression to severe COVID-19: A meta-analysis",
  "type": "peer-reviewed",
  "updated_at": "2026-10-30T12:18:02Z",
  "url": "https://research.draconitic.com/paper/c6sydarvyny0d",
  "venue": "PLOS Medicine",
  "versions": []
}